Posted by Michael Wonder on 17 Oct 2016
Decision to list cholic acid (Cholebiol) for rare disorder
17 October 2016 - PHARMAC is pleased to announce the approval of an agreement with Max Health Limited for the listing of oral cholic acid capsules (Cholebiol).
This is the sixth product to be listed following a request for proposals PHARMAC ran in 2014, related to the supply of medicines for rare disorders.
This was the subject of a consultation letter dated 28 June 2016.
In summary, the effect of the decision is that cholic acid (Cholebiol) will be funded in the community under Special Authority criteria and in DHB hospitals subject to restrictions for the treatment of bile acid synthesis disorders due to single enzyme defects with neonatal/infant-onset liver disease.
